Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (3.922)

1

Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden : Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab

enthalten in: JCO precision oncology | 2024

von Robinson, M. | Wheatley, R. | Foster, L. | +6

2

Rapid onset pembrolizumab-induced inflammatory arthritis diagnosed using musculoskeletal ultrasound

enthalten in: BMJ case reports | 2024

von Harnden, K. | Di Matteo, A. | Howell, K. | +1

3

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination

enthalten in: Journal for immunotherapy of cancer | 2024

von Watson, R. | Ye, W. | Taylor, C. | +16

4

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Milowsky, M. | O'Donnell, P. | Hoimes, C. | +20

5

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy : TROPHY-U-01 Cohort 3

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Grivas, P. | Pouessel, D. | Park, C. | +17

6

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

enthalten in: The New England journal of medicine | 2024

von Choueiri, T. | Tomczak, P. | Park, S. | +131

7

Adjuvant Immunotherapy for Kidney Cancer - A New Strategy with New Challenges

enthalten in: The New England journal of medicine | 2024

von Voss, M. | Motzer, R.

8

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy : the ARON-2 study

enthalten in: Cancer immunology, immunotherapy : CII | 2024

von Massari, F. | Santoni, M. | Takeshita, H. | +94

9

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

enthalten in: Scientific reports | 2024

von Brun, S. | Hansen, T. | Wen, S. | +5

10

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

enthalten in: Journal for immunotherapy of cancer | 2024

von Meghani, K. | Frydenlund, N. | Yu, Y. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[393]